FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washing	iton.	D.C.	20549

STATEMENT	OF CHAN	IGES IN BE	NEFICIAL (OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours nor roomanas:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Jiang V (Last)	<u>Venbin</u> (F	Reporting Person*	(Middle)		2. Issuer Name and Ticker or Trading Symbol Cytek Biosciences, Inc. [CTKB] 3. Date of Earliest Transaction (Month/Day/Year) 03/06/2024			(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title Other (specibelow) PRESIDENT AND CEO						
C/O CYTEK BIOSCIENCES, INC. 47215 LAKEVIEW BOULEVARD				4. If Amendment, Date of Original Filed (Month/Day/Year)				Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) FREMO	NT C	A	94538										•	han One Repo	
(City)	(S	state)	(Zip)		Rule	Rule 10b5-1(c) Transaction Indication									
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								to satisfy						
		Та	ble I - Non	-Deriv	ative \$	Securitie	s Ac	quired, D	isposed (of, or Be	neficially	Owned			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.					Ownership orm: Direct O) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code	Amount	(A) o (D)	Price	Transacti (Instr. 3 a	on(s)		(111341. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	ansaction			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				Co	ode V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(5)	
Employee Stock Option (right to buy)	\$7.07	03/06/2024		1	A	526,315		(1)	03/06/2034	Common Stock	526,315	\$0	526,315	D	
Restricted Stock Units	(2)	03/06/2024		1	A	353,606		(3)	(3)	Common Stock	353,606	\$0	353,606	D	

Explanation of Responses:

- 1. The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 6, 2024 and each month thereafter.
- 2. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- 3. The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on November 18 thereafter; and 4/48 of the total shares underlying the shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter.

/s/ Valerie Barnett, Attorney-in-03/08/2024 Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.